Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive PLC (AIM:GDR) Commence of roll out in Greater Manchester
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Genedrive PLC (AIM:GDR) AIHL test preliminary recommendation by NICE
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
Genedrive PLC (AIM:GDR) US FDA pre-submission for Genedrive MT-RNR1 kit
Genedrive file US FDA Pre-Submission for the Genedrive ® MT-RNR1 Product Range
Genedrive PLC (AIM:GDR) NICE includes Genedrive CYP2C19-ID Kit in new Diagnostics Assessment Programme
genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, announces that the UK’s National Institute for Health and Clinical Excellence (‘NICE’) has commenced an evaluation of CYP2C19 genotype testing for
Genedrive PLC (AIM:GDR) Point-of-Care COV19-ID Kit receives CTDA approval
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that the UK Medicines and Healthcare Products Regulatory Agency has granted a CTDA enabling the sale of the Genedrive®
Genedrive PLC (AIM:GDR) NICE issues Medtech Innovation Briefing
NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 Test
Genedrive® MT-RNR1 ID Kit Product – Video
World’s first point of care genetic test used to influence neonatal management in an acute setting and reduce aminoglycoside-induced hearing loss​​
Genedrive PLC (AIM:GDR) First NHS Deployments of Genedrive System for AIHL
First NHS Deployments of the Genedrive® System for Antibiotic Induced Hearing Loss
Genedrive PLC (AIM: GDR) Update on Point of Care Covid Test
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, provides an update on the progress being made on the Genedrive®COV19-ID kit, its rapid point of care molecular test for
Genedrive PLC (GDR.L) Investor Presentation
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it will release its interim results for the six months ended 31 December 2021 on Tuesday, 29 March 2022.